These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia. Khan MS; Butler J; Greene SJ Circ Heart Fail; 2020 Dec; 13(12):e008030. PubMed ID: 33161728 [No Abstract] [Full Text] [Related]
3. The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox. Carbone S; daSilva-deAbreu A; Lavie CJ Eur J Heart Fail; 2021 Oct; 23(10):1673-1676. PubMed ID: 34427026 [No Abstract] [Full Text] [Related]
4. Sodium-glucose co-transporter-2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness. Khunti K; Kosiborod M Diabetes Obes Metab; 2018 Apr; 20(4):763-765. PubMed ID: 29077267 [No Abstract] [Full Text] [Related]
5. Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure. Beusekamp JC; Tromp J; Boorsma EM; Heerspink HJL; Damman K; Voors AA; van der Meer P Eur J Heart Fail; 2021 Jun; 23(6):1049-1052. PubMed ID: 33899306 [No Abstract] [Full Text] [Related]
6. Diving into the unknown: sodium-glucose cotransporter-2 inhibitors in heart failure without diabetes. Seferović PM; Seferović JP; Polovina MM Eur J Heart Fail; 2019 Jul; 21(7):874-876. PubMed ID: 31112012 [No Abstract] [Full Text] [Related]
8. EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial. Liuzzo G; Patrono C Eur Heart J; 2020 Oct; 41(40):3881-3882. PubMed ID: 33026074 [No Abstract] [Full Text] [Related]
9. Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF. Bocchi EA; Biolo A; Moura LZ; Figueiredo Neto JA; Montenegro CEL; Albuquerque DC Arq Bras Cardiol; 2021 Feb; 116(2):355-358. PubMed ID: 33656089 [No Abstract] [Full Text] [Related]
10. Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors. Crea F Eur Heart J; 2020 Sep; 41(36):3379-3383. PubMed ID: 33216881 [No Abstract] [Full Text] [Related]
12. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin? Katsiki N; Triposkiadis F Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648 [No Abstract] [Full Text] [Related]